KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Debt: 2020-2024

Historic Total Debt for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Dec 2024 value amounting to $2.0 billion.

  • Regeneron Pharmaceuticals' Total Debt rose 0.10% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 0.10%. This contributed to the annual value of $2.0 billion for FY2024, which is 0.08% up from last year.
  • Regeneron Pharmaceuticals' Total Debt amounted to $2.0 billion in FY2024, which was up 0.08% from $2.0 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Total Debt high stood at $2.0 billion for FY2024, and its period low was $2.0 billion during FY2020.
  • Moreover, its 3-year median value for Total Debt was $2.0 billion (2023), whereas its average is $2.0 billion.
  • Data for Regeneron Pharmaceuticals' Total Debt shows a peak YoY grew of 0.08% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Total Debt stood at $2.0 billion in 2020, then increased by 0.08% to $2.0 billion in 2021, then increased by 0.07% to $2.0 billion in 2022, then grew by 0.08% to $2.0 billion in 2023, then climbed by 0.08% to $2.0 billion in 2024.